Evidence map›Paper›PMID 34574110›Full record

ArticleFoods (Basel, Switzerland)2021

Mingyeong Kim, Chiheung Cho, Changjun Lee, Bomi Ryu, Sera Kim, Jinyoung Hur, Sang-Hoon Lee

Open access · goldAbstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Therapeutic Potential ofLife (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Article
  6. Potential therapeutic effects of crocin.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  7. Article
  8. Antioxidants (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mingyeong KimDepartment of Food Biotechnology, University of Science and Technology, Daejeon 34113, Korea.ORCID 0000-0001-8713-5714
Chiheung ChoDivision of Functional Food Research, Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun 55365, Korea.ORCID 0000-0002-5438-3209
Changjun LeeDivision of Functional Food Research, Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun 55365, Korea.
Bomi RyuMarine Science Institute, Jeju National University, Jeju 63333, Korea.ORCID 0000-0001-5797-500X
Sera KimDivision of Functional Food Research, Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun 55365, Korea.ORCID 0000-0002-7124-5799
Jinyoung HurDivision of Functional Food Research, Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun 55365, Korea.
Sang-Hoon LeeDepartment of Food Biotechnology, University of Science and Technology, Daejeon 34113, Korea.ORCID 0000-0002-2920-4213
Korea Food Research Institute · KRJeju National University · KRKorea University of Science and Technology · KR

Funding

Ministry of Oceans and Fisheries PJT201277National Research Foundation of Korea NRF-2020R1A2C2012608
6 · The paper itself

Abstract

Advanced glycation end-products (AGEs) such as methylglyoxal (MGO) play a vital role in the pathogenesis of nephropathy, a diabetic complication. In the present study, we evaluated the anti-glycation and renal protective properties of

Indexed as

advanced glycation end-productIshige okamuraemethylglyoxalnephropathyNrf2/ARE pathway

Identifiers

PMID34574110
PMCPMC8471766
OpenAlexW3195724531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.